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Abstract
Aim Faecal markers, such as the faecal immunochemical
test for haemoglobin (FIT) and faecal calprotectin
(FCP), have been increasingly used to exclude colorectal
cancer (CRC) and colonic inflammation. However, in
those with lower gastrointestinal symptoms there are
considerable numbers who have cancer but have a nega-
tive FIT test (i.e. false negative), which has impeded its
use in clinical practice. We undertook a study of diag-
nostic accuracy CRC using FIT, FCP and urinary vola-
tile organic compounds (VOCs) in patients with lower
gastrointestinal symptoms.
Method One thousand and sixteen symptomatic patients
with suspected CRC referred by family physicians were
recruited prospectively in accordance with national refer-
ring protocol. A total of 562 patients who completed
colonic investigations, in addition to providing stool for
FIT and FCP as well as urine samples for urinary VOC
measurements, were included in the final outcome
measures.
Results The sensitivity and specificity for CRC using
FIT was 0.80 [95% confidence interval (CI) 0.66–0.93]
and 0.93 (CI 0.91–0.95), respectively. For urinary
VOCs, the sensitivity and specificity for CRC was 0.63
(CI 0.46–0.79) and 0.63 (CI 0.59–0.67), respectively.
However, for those who were FIT-negative CRC (i.e.
false negatives), the addition of urinary VOCs resulted
in a sensitivity of 0.97 (CI 0.90–1.0) and specificity of
0.72 (CI 0.68–0.76).
Conclusions When applied to the FIT-negative group,
urinary VOCs improve CRC detection (sensitivity rises
from 0.80 to 0.97), thus showing promise as a second-
stage test to complement FIT in the detection of CRC.
Keywords Faecal biomarker, faecal immunochemical
test for haemoglobin, urinary volatile organic com-
pounds, colorectal cancer
What does this paper add to the literature?
This novel study has applied both faecal and urinary
markers to improve the diagnostic accuracy for CRC
from 80% to 97%, with a negative predictive value of
100% in those with lower gastrointestinal symptoms.
Application of low-cost (< £50) diagnostic tests could
result in changes to the current clinical pathway.
Introduction
Colorectal cancer accounts for 12% of all cancers in the
UK with as strong age relationship. The clinical presenta-
tion of CRC is varied; hence the dilemma for the clinician
is to distinguish those with significant versus
nonsignificant pathology without recourse to invasive
and costly investigations [1].
Symptoms alone are not sufficiently sensitive to diag-
nose CRC, and up to a third of patients who undergo
invasive investigations have normal outcomes (i.e. colo-
noscopy reported as macroscopically and microscopically
normal) [2]. For those with lower gastrointestinal
symptoms there is increasing evidence for the use of the
faecal immunochemical test for haemoglobin (FIT) as
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first-line testing; this has a high negative predictive
value (NPV) of 0.99, but sensitivity is relatively low
(0.80–0.90) [2–4].
In symptomatic patients it remains uncertain as to
how to interpret a FIT-negative result – in other words,
can such patients be sufficiently reassured that they do
not have cancer? Alternative or additional tests are
therefore required. For example, a stool marker for
inflammation – faecal calprotectin (FCP) – or urinary
volatile metabolic markers could be utilized to risk strat-
ify those with suspected CRC. Metabolic markers such
as urinary, faecal or breath volatile organic compounds
(VOCs) have previously been shown to aid in CRC
detection [5–8]. To our knowledge, this is the first
study to use a combination of faecal tests (FIT and
FCP) as well as urinary VOC testing in a symptomatic
population suspected of CRC.
Method
Design and setting
This was a single-centre, prospective, blinded study of
patients with lower gastrointestinal symptoms referred by
family physicians to tertiary care with suspected CRC.
Ethical approval was granted by Coventry and Warwick-
shire Research Ethics Committee, UK as part of the
FAMISHED (Food and Fermentation using Metage-
nomics in Health and Disease) multicentre study (09/
H1211/38). The study protocol conforms to ethical
guidelines of the 1975 Declaration of Helsinki as
reflected by the institution’s human research committee.
Participants
A total of 1850 patients were approached with criteria
for inclusion based on national referral criteria
(Appendix S1 in the online Supporting Information).
Of these, 834 were excluded for a combination of rea-
sons including physical frailty, illness, language barriers,
etc. One thousand and sixteen patients provided con-
sent and underwent colonic investigations (endoscopic
or radiological colonic cross-sectional imaging). Sixteen
patients withdrew from the study and 310 failed to pro-
vide stool samples (69% return rate). A further 78
patients were excluded as only one stool sample was
provided (both the FIT sample collection device and
stool for FCP were required). Spot urine samples were
received from 762 patients (76% return rate), but 39
were excluded due to insufficient sample volume or
failed VOC urine analysis. This left a group of 562
patients with matching urine and stool samples (FIT
and FCP) who were included for final statistical analysis
(Fig. 1). Those who were under the age of 18, preg-
nant, did not meet the referral criteria for urgent review
for lower gastrointestinal symptoms or had incomplete
colonic examinations were excluded from the study.
All study participants were given a pack containing a
FIT sample collection device (Extel Hemo-auto MC A
device; Kyowa Medex, Tokyo, Japan via Alpha Labora-
tories Ltd., Eastleigh, UK), which holds 2 mg of faeces
in 2 ml of buffer, and a Universal Sterilin 30 ml stool
pot for the FCP sample. Written and pictorial instruc-
tions for collections were provided, with the Fe-
Col sample collection aid (Alpha Laboratories Ltd.).
Time of collection and time of receipt of samples at the
laboratory were recorded and all samples were stored
refrigerated at 2–8°C until analysis. Patients were asked
to return the sample prior to colonic investigations.
Samples returned more than 4 days after collection were
excluded from analysis.
All study participants were also provided with a
Universal Sterilin 30 ml pot to collect a spot urine sam-
ple at the time of the clinic visit. Timing of collection
was recorded and urine samples were stored with sealed
caps in a freezer at 80°C. For patients who were
unable to provide the sample in the clinic, a urine con-
tainer was provided as well as a return envelope, and
the sample was sent via courier from their primary
physician and stored at 80°C.
Intervention
Quantitative FIT was performed on automated HM-
JACKarc analyser (Kyowa Medex) by the Midlands and
North West Bowel Cancer Screening Hub, Rugby, UK
on a weekly basis. Stool samples for FCP analysis were
extracted manually by trained laboratory staff alongside
the routine calprotectin service. Extracted calprotectin
was measured using the EliA Calprotectin fluoroim-
munoassay on the automated Thermo Fisher Immuno-
Cap 250 analyser (Thermo Fisher Scientific, Waltham,
Massachusetts, USA).
In the analyses for CRC, thresholds were determined
from the data (a priori) to maximize sensitivity under
the constraint that the NPV was ≥ 0.99. For FCP, no
threshold achieved an NPV ≥ 0.99. The lowest detec-
tion limit of this assay for FIT is 3 lg/g faeces.
Samples were initially stored at 80°C. Prior to uri-
nary VOC analysis, they underwent a graded defrost
process (based on our unpublished established proto-
col). Ten-millilitre glass vial aliquots (Thermo-Fisher
Scientific, Loughborough, UK) suitable for use with an
autosampler (MPS, Gerstel GmbH, Mu¨lheim an der
Ruhr, Germany) were used. Crimp caps (Chromacol
Ltd., Merck, UK) with silicone polytetrafluoroethylene
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septa were used to seal each sample. Each septum and
crimp cap was baked for 6 h at 200°C prior to use to
remove any potential interfering molecules. Control
blanks of air were prepared using the same method. A
commercial gas analysis instrument [Lonestar (FAIMS),
Owlstone, Cambridge, UK], based on ion mobility spec-
troscopy (IMS), was used to analyse VOCs emanating
from the urine samples. Details of the Lonestar and its
application in medical diagnostics have been reviewed by
Covington et al. [9]. The setup was bespoke for this appli-
cation, to detect unique VOC chemical ‘fingerprints’. Our
previous study has determined the optimal sample capture
and storage methods to minimize diurnal and day to day
variation [10] (see Appendix S1 for further methodologi-
cal details on the use of FAIMS).
Outcomes
Participating clinicians, endoscopists and radiologists
were blinded to the results of the urinary VOCs and
faecal tests (FIT/FCP). Diagnosis of CRC and adeno-
mas was confirmed histologically. High-risk adenomas
were defined as lesions with high-grade dysplasia and/
or serrated, villous histology, ≥ 10 mm in size or the
presence of three or more adenomas. Hyperplastic
polyps were excluded. Faecal and urinary VOC results
were compared with the outcome of the colonic investi-
gations and divided into clinical groups: CRC, high-risk
adenoma, all adenomas, others and normal.
All analysis was carried out using R 3.4.2 (R Foun-
dation for Statistical Computing, Vienna, Austria). To
combine FIT and FCP measurements, 10-fold cross val-
idation and a Bayesian robust logistic regression model
were used to generate predictive scores for each patient
using the above criteria.
The VOC data variables were assessed for predictive
value with a Mann–Whitney U-test at a significance
level of 0.8, with multi-test correction performed using
sequential goodness of fit (SGoF) [11]. This yielded a
set of about 104 candidate variables. The dimensional-
ity of the selected variables was then reduced using
principal component analysis (PCA) [12], with the
number of principal components chosen using cross-
validation (typically around 35) [13]. For testing using
VOCs alone, a logistic regression model was trained
on the results. For the two-phase test incorporating
FIT as a first phase a support vector machine, radial
kernel, was used on the top 128 variables, without
using SGoF for variable selection. Ten-fold cross-vali-
dation was used to generate predictive scores for each
patient, and a threshold was selected to maximize
sensitivity.
Results
The main patient characteristics are shown in Table 1.
A total of 562 patients, who completed colonic investi-
gations, in addition to providing stool for FIT and FCP
Excluded
N = 39
Urine
samples
N = 762
N = 562
Returned
Returned
Total approached; N = 1850 Matching urinary VOC &
faecal biomarkers for final
analysisTotal recruited; N = 1016,
Withdrew: N = 16
VOC analysis
N = 723
N = 690
Stool samples
N = 612
FIT & FCP
N = 78
(details described
in text)
(details described
in text)
Excluded
Figure 1 Study flow diagram of the total
number of patients recruited via the
urgent colorectal lower gastrointestinal
pathway who met the inclusion criteria.
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as well as urine samples for urinary VOC measurements,
were included in the final statistical analysis.
Faecal biomarkers (FIT and FCP)
The use of FIT alone for CRC detection revealed a sen-
sitivity of 0.80 [95% confidence interval (CI) 0.66–
0.93] and specificity of 0.93 (95% CI 0.91–0.95). The
area under the curve (AUC) was 0.90 (95% CI 0.85–
0.96). The NPV was 0.99 (95% CI 0.98–1.0).
For high-risk adenomas, applying threshold of 3 lg/
g faeces which is the lowest detection limit of the assay,
the sensitivity was 0.70 (CI 0.52–0.87), specificity of
0.66 (CI 0.623–0.703) with a NPV of 0.98
(CI 0.96–0.99) (see Table 2 for the diagnostic perfor-
mance of FIT).
FCP alone performed less well than FIT in the CRC
and adenoma groups. Test performances combining
FIT and FCP are shown in Table 2. The respective
receiver operator curve characteristics (ROCs) for CRC,
high-risk adenomas and all adenomas using FIT are
shown in Fig. 2.
Urinary VOCs
For urinary VOC analysis, logistic regression using
SGoF selection and PCA was applied to form a unique
‘chemical fingerprint’. The sensitivity of urinary VOCs
Table 1 Patient demographic to include clinical characteristics and main diagnostic outcomes.
Characteristic n (%)
Median FIT
(lg/g faeces)
Median FCP
(lg/g faeces)
Total 562
Male gender 286 (51)
Median age (years) (range) 68 (29–89)
Presenting symptoms*
Altered bowel habit 369 (66)
Weight loss 87 (15)
Rectal bleeding 232 (41)
Anaemia 121 (22)
Iron-deficiency anaemia 91 (16)
Abdominal pain 164 (29)
CRC 35 (6.2) 270 86
High-risk adenoma 27 (4.8) 14 23
All adenomas (low and high risk) 94 (17) 3.5 19
Others (DD, IBD, MC etc.) 173 (31) 1.8 21
Normal 233 (41) 1.4 16
Normal – no colonic pathology identified.
DD, diverticular disease; IBD, inflammatory bowel disease; MC, microscopic colitis.
*Note that some patients may present with a constellation of symptoms.
Table 2 Diagnostic performance of FIT alone and in combination with FCP for CRC, high-risk adenoma and all adenomas.
Disease group Sensitivity (CI) Specificity (CI) NPV (CI) PPV (CI) AUC (CI)
FIT
CRC (n = 35) 0.80 (0.66–0.93) 0.93 (0.91–0.95) 0.99 (0.98–1.0) 0.44 (0.32–0.56) 0.90 (0.85–0.96)
High-risk adenoma (n = 27) 0.63 (0.44–0.81) 0.76 (0.72–0.79) 0.98 (0.96–0.99) 0.11 (0.07–0.17) 0.73 (0.63–0.83)
All adenomas (n = 94) 0.53 (0.43–0.63) 0.68 (0.63–0.72) 0.88 (0.84–0.91) 0.25 (0.19–0.31) 0.63 (0.58–0.69)
FIT + FCP
CRC (n = 35) 0.80 (0.66–0.93) 0.93 (0.91–0.95) 0.99 (0.97–1.0) 0.43 (0.31–0.55) 0.91 (0.86–0.96)
High-risk adenoma (n = 27) 0.93 (0.81–1.0) 0.25 (0.21–0.29) 0.99 (0.96–1.0) 0.06 (0.04–0.08) 0.69 (0.59–0.79)
All adenomas (n = 94) 0.86 (0.79–0.93) 0.26 (0.22–0.30) 0.90 (0.85–0.95) 0.19 (0.15–0.23) 0.60 (0.54–0.67)
High-risk adenoma: adenoma with high-grade dysplasia, villous histology, ≥ 10 mm or ≥ 3 adenomas.
Thresholds applied to achieve the highest sensitivity under the constraint of keeping the negative predictive value > 0.99.
Note that the lowest limit of detection for the FIT assay is 3 lg/g feces.
ª 2018 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of
Coloproctology of Great Britain and Ireland.4
Faecal and urinary markers in colorectal cancer M. M. Widlak et al.
for the detection of CRC was 0.63 (95% CI 0.46–0.79)
and specificity was 0.63 (95% CI 0.59–0.67). The AUC
was 0.67 (95% CI 0.57–0.77) and the NPV was 0.96
(95% CI 0.94–0.98).
For high-risk adenoma and all adenomas, using uri-
nary VOCs the sensitivity was 0.93 (95% CI 0.81–1.0)
and 0.91 (95% CI 0.85–0.97), respectively, with speci-
ficity of 0.16 (95% CI 0.13–0.20) and 0.15 (95% CI
0.12–0.19), respectively (Table 3).
Combining FIT and urinary VOCs
When used in combination (FIT and urinary VOCs) for
CRC, the sensitivity was 0.80 (95% CI 0.66–0.93) and
specificity was 0.89 (95% CI 0.87–0.93). The AUC was
0.86 (95% CI: 0.77–0.94) and the NPV 0.99 (95% CI:
0.97–1.0).
Further analysis of urinary VOCs in a setting of FIT-
negative CRC (missed cancer) improved the sensitivity
to 0.97 (95% CI 0.90–1.0) and specificity to 0.72 (95%
CI 0.68–0.76) with a NPV of 1.0 (95% CI 0.99–1.0).
Figure 3 shows a box plot applying the two-stage filter
process to depict improvement in CRC detection when
urinary VOCs are used in FIT-negative CRC patients
compared with FIT alone. The decision threshold line
in each case is the value (of either FIT or predicted
probability) that divides prediction of cancer. Thus, for
any patient above the line the test indicates the likeli-
hood of having cancer, and vice versa. Overall, patients
are classed as negative for the two-stage test if they are
negative for both FIT and VOC screening, and positive
if they are positive for either test – FIT (above the
threshold) or VOC screening. We did not observe any
differences even after stratifying for age or gender. For
all adenomas, urinary VOC did not improve detection
in those with false-negative FIT.
Discussion
Whilst studies evaluating various faecal markers (methy-
lated genes, microRNA and protein markers) have
shown promise for the detection of CRC and adenomas
their application within a clinical setting has been lim-
ited due to high cost and poor sensitivity, especially
when applied in areas with a low disease prevalence
[14]. Thus, the emphasis has been on low-cost, non-
invasive testing such as FIT for detection of CRC and
adenomas. Experience from using FIT in the screening
population reveals that it has a relatively high specificity
at the expense of sensitivity. Various FIT devices have
been trialled and it has become evident that there is
considerable heterogeneity in FIT devices for the
CRC (AUC = 0.9)
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Figure 2 Respective ROC curves for (a) CRC, (b) high-risk adenoma and (c) all adenomas using FIT.
Table 3 Diagnostic performance of urinary VOCs for CRC, high-risk adenoma and all adenomas.
Disease group Sensitivity (CI) Specificity (CI) NPV (CI) PPV (CI) AUC (CI)
CRC (n = 35) 0.63 (0.46–0.79) 0.63 (0.59–0.67) 0.96 (0.94–0.98) 0.10 (0.06–0.14) 0.67 (0.57–0.77)
High-risk adenoma (n = 27) 0.93 (0.81–1.0) 0.16 (0.13–0.20) 0.98 (0.94–1.0) 0.05 (0.03–0.07) 0.56 (0.45–0.68)
All adenomas (n = 94) 0.91 (0.85–0.97) 0.15 (0.12–0.19) 0.90 (0.83–0.96) 0.18 (0.15–0.21) 0.55 (0.49–0.61)
High-risk adenoma (HRA) - adenoma with high-grade dysplasia, villous histology, ≥ 10 mm or ≥ 3 adenomas.
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detection of CRC. This is further compounded by the
fact that various threshold levels are applied and there is
uncertainty surrounding those who test negative with
FIT [15].
In the UK, CRC detection based on symptoms alone
is low; ranging from 4% to 8% [16,17]. This suggests
that over 90% of patients undergo negative tests for
exclusion of CRC. Thus, it is imperative that alternative
noninvasive prescreening markers such as FIT and other
faecal or urinary markers are used in those with gas-
trointestinal symptoms so as to minimize unnecessary
investigations.
In this study we have shown for the first time the
value of dual-modality testing using noninvasive markers
(FIT and urinary VOCs) as a two-stage process to
exclude CRC. In those with lower gastrointestinal
symptoms suspicious of CRC, the use of FIT alone
revealed a sensitivity of 80% [meta-analysis suggests 90%
(CI 87–92%); unpublished]. Thus, there is the potential
to miss one or two cancers out of every ten, which is
not sufficiently robust for everyday clinical use. Urinary
VOC on its own was less sensitive (0.63; CI 0.46–0.79)
and in combination with FIT did not show any
improvement in sensitivity (0.80; CI 0.60–0.93). How-
ever, the use of a two-stage test, namely the addition of
urinary VOC testing in those who test negative for FIT
(i.e. false-negative CRC), increases the combined
sensitivity to 97%; this is more acceptable for clinical
use and comparable to the performance of colonoscopy
at a fraction of the cost.
Urinary VOC analysis on its own (VOC ‘positive’)
only provides 63% sensitivity and specificity for CRC
detection, and performance does not improve when it is
used in combination with FIT or FCP. This may be
due to the heterogeneity of the chemical fingerprint
that is produced by CRC. However, following preselec-
tion by FIT it performs well, as there is reduced back-
ground ‘volatile noise’ making it more specific to detect
either haemoglobin moiety/breakdown products or gly-
cation end-products. Whilst urinary VOCs demonstrate
a high sensitivity for adenoma detection, the lack of
specificity and high false-positive rate suggests that this
marker may not perform as well for adenoma detection.
The VOCs that are detected using our preanalytical
method and FAIMS are unique, as detection is based
on volatiles existing in the gaseous phase rather than in
the liquid phase. The disease separation is characterized
by the mobility of individual ions (i.e. physical rather
than chemical properties of the ion), which have low
molecular weights (20–200 kDa). Unlike conventional
gas chromatography and mass spectroscopy (GC-MS),
the specific chemicals are not identified but a ‘chemical
fingerprint’ is formed. GC-MS is limited by its high
running and labour cost as well as run time. This
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Figure 3 Two plots showing the stages of the FIT/VOC two-stage test. The left-hand plot shows the distribution of FIT measure-
ments for CRC-positive and CRC-negative patients. The dotted line shows the threshold for the first stage test. Patients above this
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impedes its use within routine clinical practice where
rapid, low cost and simple operation (nonskilled opera-
tors) would be preferable. The composition of key vola-
tile compounds gives rise to the unique chemical
fingerprint identified in this study, allowing classification
into ‘VOC positive or negative’ outcomes.
VOCs reflect metabolic cellular changes within the
host; for example, detection of advanced glycation end-
products which have been implicated in colon carcino-
genesis [18]. Our previous work [19] [undertaken using
a Bruker Scion GCMS, fitted with dynamic head space
sampling and solid-phase micro-extraction (SPME) pre-
concentration system] has identified three chemicals
which are modulated in CRC – the ‘VOC positive’ signa-
ture. In particular we noted a high incidence of 1,3,5,7-
cyclooctatetraene and a low incidence of 1,3-propanedia-
mine and 4-methylbenzoic acid (dietary metabolite).
Methylbenzene has also recently been reported to pro-
vide a unique chemical signature in those with CRC
when a different technology (non-GCMS) is used [20].
A higher incidence of acetone was noted in those with
colorectal adenomas; this has been shown by members of
our group (unpublished) to be produced by C. difficile
and in other Clostridiales. Allyl isothiocyanate was also
detected in those with CRC but not at elevated levels;
the latter is produced by certain E. coli strains as dietary
substrates with can affect the integrity of the gut mucosa
[21].
The use of dual-modality testing, initially with FIT
followed by urinary VOCs, enables 97% sensitivity with
100% NPV if both tests are negative for the detection
of CRC and high-grade adenomas. Furthermore, find-
ings from this study suggest that the combination of
FIT and VOC offers the option for personalized strate-
gies for CRC detection in those with symptoms and
avoids the need for repeat FIT testing (if FIT is nega-
tive the test probability is unlikely to improve unless
there are preanalytical errors).
It is envisaged that both these noninvasive tests (FIT
and urinary VOCs) can be undertaken within primary
care and analysed within a central laboratory (as FIT
currently is) at low cost to guide secondary care referral
patterns. The FAIMS unit is commercially available and
urine VOCs are deemed stable up to 12 months when
stored frozen [10]. It has been purported within a
simulation model that for an equivalent biomarker to
compare with FIT (£18/test) it should not exceed
seven-fold the unit cost of FIT [22] – this is fulfilled in
urinary VOCs (£28/test), which cost less than twice the
unit cost of FIT. A proposed clinical algorithm is out-
lined, highlighting the use of a dual noninvasive diag-
nostic approach in those with lower gastrointestinal
symptoms (Figure S1).
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Clinical pathway – lower gastrointestinal
symptoms suspicious of colorectal cancer.
Appendix S1. Methods.
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